Warning Letter — Happiest Baby, Inc.
The FDA issued a Warning Letter to Happiest Baby, Inc. for distributing an adulterated device that lacks the required Investigational Device Exemption (IDE) or Premarket Approval (PMA).
Happiest Baby, Inc., as well as regulatory and clinical operations teams at medical device companies managing investigational studies or premarket applications.
The classification of a device as adulterated due to the absence of an IDE or PMA suggests significant regulatory gaps in the company's clinical or premarket pathway. This indicates that the FDA has identified either unapproved clinical research or the marketing of a high-risk device without required pre-market authorization. Regulatory teams must interpret this as a signal that the agency is strictly enforcing pre-market requirements for novel or high-risk devices in this product category.
QA and Regulatory teams should review existing clinical study protocols and marketing materials to ensure no high-risk devices are being evaluated or marketed without the necessary IDE or PMA clearances. Verify that any device requiring clinical data for a future submission is operating under a valid exemption before enrolling participants.
FDA Warning Letter issued to: Happiest Baby, Inc.. Center for Devices and Radiological Health — Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device. Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/happiest-baby-inc-718306-06152026
Open in openFDA / FDA.gov